# Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

> **NCT03768089** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 115 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Placebo (matched to VX-121 suspension)
- **DRUG:** VX-121 (Suspension)
- **DRUG:** TEZ/IVA
- **DRUG:** IVA
- **DRUG:** Placebo (matched to TEZ/IVA)
- **DRUG:** Placebo (matched to IVA)
- **DRUG:** VX-121 (Tablet)
- **DRUG:** Placebo (matched to VX-121 tablet)

## Key facts

- **NCT ID:** NCT03768089
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-20
- **Primary completion:** 2019-05-03
- **Final completion:** 2019-05-03
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03768089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03768089, "Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03768089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*